Research institutionUnited Statestimi.org
The TIMI Study Group is an academic research organization (ARO) dedicated to advancing the knowledge and care of patients with cardiovascular disease and its risk factors through rigorous multicenter clinical trials and analyses.
Founded in 1984 by the U.S. National Heart, Lung, and Blood Institute (NHLBI), it is headquartered at Brigham and Women’s Hospital in Boston, Massachusetts, and serves as an affiliate of Harvard Medical School within the Mass General Brigham system. Under leadership including Dr. Marc Sabatine, it has conducted over 70 to 80 trials spanning phase I to IV, enrolling from small cohorts to more than 26,000 participants across more than 50 countries and 5,000 sites.
The group investigates a wide range of interventions, including fibrinolytic, antithrombotic, antiplatelet, lipid-modifying (such as PCSK9 inhibitors), anti-inflammatory, anti-diabetes, and anti-obesity agents, as well as percutaneous coronary intervention, in patients with acute coronary syndromes, stable coronary disease, stroke, peripheral artery disease, dyslipidemia, diabetes, obesity, atrial fibrillation, and heart failure. It also maintains extensive databases for biomarker, genetic, and health-economic analyses to support personalized medicine and cost-effectiveness evaluations.
As a leading non-profit ARO in the cardiovascular research field, TIMI collaborates with industry sponsors, NIH, and other academic groups like the Duke Clinical Research Institute on global trials and secondary analyses that have shaped clinical practice guidelines and improved patient outcomes worldwide.
Also known as Thrombolysis In Myocardial Infarction Study Group and TIMI Study Group at Brigham and Women's Hospital.
None yet. When a new project in the record names TIMI as owner, partner or investor, it shows here.
Data show early LDL‑C lowering with Repatha reduces major cardiovascular events and is cost‑effective for high‑risk patients without prior heart attack or stroke.
